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BY-NC-ND license (http://creativecomAbstract Background/Purpose: To investigate the in vitro and in vivo activity of imipenem-
colistin combination against multidrug-resistant Enterobacter cloacae infections in order to
determine whether it should be explored further.
Methods: The antimicrobial activity of colistin alone and in combination with imipenem was
assessed versus an imipenem-susceptible isolate, E. cloacae GN1059, or an imipenem-
resistant strain, E. cloacae GN0791, isolated in Anhui, China. The potential synergy of
imipenem-colistin was evaluated using a checkerboard assay, as well as static time-kill exper-
iments at 1 and 2 minimum inhibitory concentration (MIC). A simple invertebrate model
(Galleria mellonella) was developed to assess the in vivo efficacy of imipenem-colistin in
treating E. cloacae infection.
Results: In checkerboard assays, synergy (defined as a fractional inhibitory concentration in-
dex of  0.5) was observed between imipenem and colistin for both isolates tested. In time-
kill assays, the combination of imipenem-colistin at 1 or 2 MIC resulted in complete killing
of both strains. In the G. mellonella larvae model infected with lethal doses of E. cloacae, theof Infectious Diseases, The First Affiliated Hospital of Anhui Medical University, Jixi Road, Number
hu.com (J. Li).
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(2016), http://dx.doi.org/10.1016/j.combination therapy led to significantly increased survival of the larvae as compared with imi-
penem or colistin monotherapy alone (p < 0.05).
Conclusion: This is the first report demonstrating the efficacy of antimicrobial agents in the G.
mellonella larvae model of infections caused by E. cloacae. Our study suggested that
imipenem-colistin combination was highly active against E. cloacae both in vitro and in the
simple invertebrate model, and provided preliminary in vivo evidence that such combination
might be useful therapeutically.
Copyright ª 2016, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Introduction
Enterobacter cloacae recently emerged as an important
nosocomial opportunistic pathogen responsible for various
nosocomial infections, including bacteremia, lower respira-
tory tract infections, skin and soft-tissue infections, urinary
tract infections, and intra-abdominal infections. E. cloacae
has a tendency to develop resistance during the course of
treatment and, hence, at least two antibiotics should be
prescribed simultaneously for serious infections.1,2
Imipenem (IMP), a subgroup of carbapenems, has an
extremely broad spectrum of activity against both Gram-
positive and -negative bacteria, including E. cloacae. With
increased reports about carbapenem-resistant E. cloacae
clinical isolates, nosocomial life-threatening infections are
only treatable with a limited number of agents, such as
colistin (COL).3,4 The synergy of combinations of COL and
rifampin or IMP against an metallo-b-lactamase-producing
E. cloacae strain was reported by Tascini et al.5 Another
study showed that IMP in combination with COL was
effective against multiple drug resistant (MDR) E. cloacae,
and this combination successfully treated a case of severe
E. cloacae-related pneumonia.6
Although this combination appears to be a promising
treatment option based on in vitro data, further testing in
animal models is needed in order to predict their suitability
for clinical use in humans. Mammalian models are routinely
employed for such studies, since the data generated aremost
relevant to human infections; however, their use poses sig-
nificant practical, financial, and ethical barriers. As a result,
invertebrate models, such as Galleria mellonella larvae,
have been proposed as inexpensive and easy alternatives to
investigate the in vivo activity of antimicrobial agents. A
number of studies recently used this model to investigate the
in vivo activity of antimicrobial agents versus Acinetobacter
baumannii among other pathogens.7e10
Here, we employed the G. mellonella infection model to
study the in vivo activity of IMP-COL combination against
MDR E. cloacae in an attempt to determine whether it
should be explored further.Methods
Bacteria, insects, and antimicrobial susceptibility
testing
Two clinical isolates of E. cloacae were isolated at tertiary
care hospitals located in Anhui, China, in 2013. E. cloacaeang H, et al., Enhanced efficacy
itro activity and a Galleria mello
jmii.2016.01.003GN1059 was isolated from the blood of a patient diagnosed
with brain-stem infarction and admitted to the Intensive Care
Unit. E. cloacae GN0791 was isolated from the sputum of a
patientwhowas admitted to the neurosurgeryward (Table 1).
Batches of G. mellonella larvae (Kaide Ruixin Co., Ltd.,
Tianjin, China) in their final instar stage were stored in the
dark at 4C and usedwithin 7 days of shipment. Larvaemasses
varied slightly, but were typically 250 mg, and this value was
used to calculate treatment doses. All tested antibiotics,
including colistin sulfate, were obtained from Sigma-Aldrich
(St. Louis, MO, USA). Minimum inhibitory concentrations
(MICs) were determined by Clinical and Laboratory Standards
Institute (CLSI) reference broth microdilution methods.11
Susceptibility was determined using CLSI breakpoints.
Synergy testing by checkerboard assay
Synergy between IMP and COL was assessed using the micro-
titer plate checkerboard assays as described previously.12 In
brief, 96-well microtiter plates were set up with increasing
concentrations of IMP (0.06e256mg/L) in the horizontal wells
and COL (0.06e4 mg/L) in the vertical wells, and inoculated
with 5  105 CFU/mL E. cloacae prepared in LB broth. Plates
were incubated at 37C for 24 hours and visually inspected for
turbidity to determine growth. Synergy was assessed by the
calculation of fractional inhibitory concentration index (FICI)
and susceptible breakpoint index (SBPI) as previously
described. SBPI was calculated as ([COL susceptibility break-
point]/[MIC of COL in combination with IMP])þ([IMP suscep-
tibility breakpoint]/[MIC of IMP in combination with COL]).
Synergy was defined as FICI  0.5 and SBPI > 2.13
Time-kill assays
Time-kill assays were conducted for each strain using IMP or
COL alone and in combination according to a previously
describedmethodology.12 Each experimentwas performed in
duplicate to ensure reproducibility. In brief, antimicrobial
regimens consisted ofmultiples of theMIC (1 and 2MIC) of
IMP or COL alone or in combination. LB broth was inoculated
with 5  105 CFU/mL of the strains and incubated at 37C.
Colony counts were obtained at 0 hours, 2 hours, 4 hours,
8 hours, and 24 hours to determine the viable CFU/mL. The
lower limit of detection was set at 10 colonies (1 log10 CFU/
mL). Synergy was defined as a  2 log10 CFU/mL decrease
between the combination and the most efficient agent alone
at 24 hours. Bactericidal activity was defined as a  3
log10 CFU/mL reduction in cell numbers compared with the
initial inoculum after 24 hours.of imipenem-colistin combination therapy against multiple-drug-
nella model, Journal of Microbiology, Immunology and Infection
Table 1 Summary of in vitro synergy testing and treatment efficacy in Galleria mellonella against two Enterobacter cloacae
strains.
Antibiotic MIC (mg/L) FICI a SBPI a Time-kill assay results b G. mellonella survival (%) c
GN1059 GN0791 GN1059 GN0791 GN1059 GN0791 GN1059 GN0791 GN1059 GN0791
Control d d d d d d Growth Growth 6.25  6.25 4.17  3.60
IMP 0.5 64 d d d d Bactericidal,
regrowth at 24 h
Bactericidal,
regrowth at 24 h
70.67  9.60 8.33  3.60
COL 0.5 1 d d d d Bactericidal,
regrowth at 24 h
Bactericidal,
regrowth at 24 h
56.25  6.25 27.08  3.60




95.83  3.60 85.42  7.21
a As observed in three independent experiments.
b IMP at 2 MIC inhibited the growth of both strains, and this inhibitory effect persisted for 24 hours.
c G. mellonella survival at 96 hours after infection; values are means from three replicate experiments  standard deviation.
COL Z colistin; FICI Z fractional inhibitory concentration index; IMP Z imipenem; IMPþCOL Z imipenem-colistin combination;
MIC Z minimum inhibitory concentration; SBPI Z susceptible breakpoint index.
Imipenem-colistin combination against E. cloacae 3
+ MODELG. mellonella-killing and -treatment assays
The G. mellonella-infection model was adapted from that
proposed for A. baumannii by Peleg et al.14 All experiments
were approved in advance by the Animal Care and Use
Committee of Anhui Medical University, Hefei, China. E.
cloacae GN1059 and GN0791 were grown overnight in LB
broth and washed twice in sterile phosphate buffered saline
(PBS). In order to establish the inoculum required to kill G.
mellonella over 48e96 hours, 10 larvae were inoculated
with 10 mL of bacterial suspensions containing approxi-
mately 104 CFU/larva, 105 CFU/larva, and 106 CFU/larva of
bacteria in PBS. Bacteria were injected into the hemocoels
through the last left proleg using a 50-mL Hamilton syringe
(Hamilton Company, Shanghai, China). Larvae were incu-
bated in petri dishes lined with filter paper at 37C and
observed daily for 4 days. Insects were considered dead if
they failed to respond to touch. For antimicrobial treat-
ment assays, 16 larvae were infected with a lethal dose of
E. cloacae GN1059 or GN0791 as described above. Antibi-
otics were administered via 10-mL injections into the last
right proleg within 2 hours of inoculation. Doses were
chosen to mimic those used to treat human infections and
consisted of IMP at 15 mg/kg and COL at 2.5 mg/kg. IMP or
COL was assessed individually, and IMP-COL combination
was also assessed. Treatment was given only once. Sixteen
uninjected larvae and 16 larvae injected with 10 mL of
sterile PBS in place of bacteria were used as controls. To
allow for the trauma associated with double injections,
uninfected larvae inoculated twice with 10 mL PBS were
also used. The larvae were observed for survival every
24 hours for 4 days. Experiments were performed three
times on separate occasions. The survival rate (and stan-
dard deviation) of larvae at the 96-hour assay endpoint was
calculated using pooled data across replicate experiments.
Statistical analysis
All statistical analyses were performed using GraphPad
Prism, version 5.04 (GraphPad Software Inc., San Diego, CA,
USA). Survival curves were analyzed using the log-rank test,
with a p  0.05 indicating statistical significance.Please cite this article in press as: Yang H, et al., Enhanced efficacy
resistant Enterobacter cloacae: in vitro activity and a Galleria mello
(2016), http://dx.doi.org/10.1016/j.jmii.2016.01.003Results
Antimicrobial susceptibility
E. cloacae GN1059 was susceptible to all agents, including
b-lactams, aminoglycosides, quinolones, COL, and tigecy-
cline. The MIC of COL against GN1059 was 0.5 mg/L.
GN0791 was resistant to all agents tested, but susceptible
to COL (MIC Z 1 mg/L) and tigecycline. The MIC of IMP
against GN1059 and GN0791 was 0.5 mg/L and 64 mg/L,
respectively.
Checkerboard assays
In microtiter checkerboard assays, the presence of COL at
0.125 mg/L reduced the IMP MIC from 0.5 mg/L to 0.06 mg/
L against GN1059. For GN0791, the presence of COL at
0.25 mg/L reduced the IMP MIC from 64 mg/L to 4 mg/L. A
FICI < 0.5 was observed for both strains, indicative of a
potent synergistic interaction. An SBPI > 2 was also
repeatedly seen for both strains, providing further evidence
of the strength and clinical relevance of the combination
(Table 1).
Time-kill assays
COL at 1 or 2 MIC completely inhibited the growth of
GN1059 or GN0791 after 4 hours incubation, but did not
provide sustained killing over 24 hours, despite the
apparent susceptibility of both strains to COL in static as-
says (Figure 1). IMP at 1 MIC reduced the growth of
GN1059 or GN0791 to w2 log10 CFU/mL after 8 hours in-
cubation. However, both strains then regrew to reach the
level of the control after 24 hours (Figures 1A and 1C). IMP
at 2 MIC completely inhibited the growth of both strains
after 2 hours, and this inhibitory effect persisted for
24 hours (Figures 1B and 1D).
By contrast, the combination of IMP and COL at 1 or 2
MIC displayed both rapid and consistently bactericidal ac-
tivity, resulting in complete killing without regrowth over
the time course of the assay for each of the strains.of imipenem-colistin combination therapy against multiple-drug-
nella model, Journal of Microbiology, Immunology and Infection
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Both GN1059 and GN0791 were pathogenic to G. mello-
nella at > 104 CFU/larva. Most of the killing occurred in the
first 24 hours, followed by further killing in the subsequent
3 days. The mortalities at 4 days were 100% at 106 CFU/
larva and between 70% and 90% at 105 CFU/larva. Based on
these data, 5  105 CFU/larva of both strains was selected
as the inoculum for subsequent treatment experiments.Activities of IMP and COL in the G. mellonella
model
Administration of COL protected G. mellonella from
GN1059-mediated killing, as > 56% of the larvae were still
alive at 96 hours postinoculation. However, COL mono-
therapy performed poorly as compared with the IMP-COL
combination versus GN0791 (Figure 2B). The survival rate
of COL to GN0791-infected larvae was 27.08% ( 3.60) as
compared with 56.25% ( 6.25) when COL was used to treat
GN1059-infected caterpillars (p < 0.05; Table 1). IMP was
effective versus the IMP-susceptible isolate GN1059; how-
ever, when IMP was used to treat GN0791 infections, sur-
vival rates were equivalent to those for the untreated
controls as predicted from the in vitro susceptibility data
(Table 1, Figure 2A).
The combination of COL with IMP was highly effective in
protecting larvae from GN1059 or GN0791 lethal infections,
with survival > 85% in both cases, and was obviouslyFigure 1. Time-kill assay performed on (A,B) Enterobacter cloac
1 MIC or (B,D) 2 MIC and an imipenem-colistin combination.
combination; open squares, imipenem; filled squares, colistin. Da
inhibitory concentration.
Please cite this article in press as: Yang H, et al., Enhanced efficacy
resistant Enterobacter cloacae: in vitro activity and a Galleria mello
(2016), http://dx.doi.org/10.1016/j.jmii.2016.01.003superior to COL monotherapy in the treatment of GN0791
(p < 0.05; Table 1, Figure 2).
Discussion
Carbapenem-resistant Enterobacteriaceae (CRE) continue
to emerge as a serious public health threat worldwide.15e17
With the increased resistance to carbapenem, unorthodox
combination therapies are increasingly being considered.
Recently, Lin et al6 reported that high-dose IMP alone or in
combination with COL was effective against a multidrug-
resistant, IMP-susceptible E. cloacae. Additionally, the
in vitro synergistic effect of this combination was also
shown; however, one limitation of their study was that they
did not include an isolate that was not susceptible to IMP.6
In our study, we used the checkerboard assay and time-
kill method to evaluate synergistic effects against IMP-
susceptible and -resistant strains of E. cloacae. In check-
erboard assays, synergy between COL and IMP was repeat-
edly observed, with FICIs < 0.5 and SBPIs > 2. A reduction
of IMP MIC in the presence of sub-inhibitory concentrations
of COL was observed against both strains. SBPI is a novel
parameter that relates the magnitude of the interaction to
the pharmacodynamic breakpoints used to determine sus-
ceptibility in vivo. An SBPI > 2 indicates that the agents are
more active in combination than when used alone.13 Sur-
prisingly, COL at 1 or 2 MIC was initially bactericidal, but
significant regrowth was observed at 24 hours, despite the
apparent susceptibility of both strains to COL in vitro. Thisae GN1059 or (C,D) GN0791 using imipenem or colistin at (A,C)
Key: open circles, control; filled circles, imipenem-colistin
ta from a single representative experiment. MIC Z minimum
of imipenem-colistin combination therapy against multiple-drug-
nella model, Journal of Microbiology, Immunology and Infection
Figure 2. Survival curves for Galleria mellonella larvae
inoculated with a lethal dose of (A) Enterobacter cloacae
GN1059 or (B) GN0791 following treatment with imipenem
(15 mg/kg), colistin (2.5 mg/kg), or an imipenem-colistin
combination. Curves represent a single experiment per-
formed using 16 insects. COL Z colistin; IMP Z imipenem;
IMPþCOLZ imipenem-colistin combination; PBSZ phosphate-
buffered saline.
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resistance” as described previously.18,19 Although a formal
population analysis was not performed in our study, it
seems likely that COL exposure selected for a hetero-
resistant subpopulation during the course of the time-kill
study. Accordingly, despite its apparent susceptibility to
COL, MDR E. cloacae should not be treated with COL mon-
otherapy. IMP at 1 MIC also did not provide sustained
killing over 24 hours. The reason for this may be similar to
“colistin heteroresistance”, but be called “imipenem het-
eroresistance”. Some studies reported that imipenem het-
eroresistance can be induced by IMP in A. baumannii and
Klebsiella pneumoniae strains.20e22 By contrast, the IMP-
COL combination displayed both rapid and sustained
bactericidal activity at 1 or 2 MIC over the time course
of the time-kill assay for each strain. The synergistic effect
of the IMP-COL combination was reported in many studies,
especially against A. Baumannii.6,23 To our knowledge,
there is only one study reporting the in vitro synergy of IMP-
COL combination against a IMP-susceptible E. cloacae,6 and
our results were in line with their findings; however, the
synergy effect was also found against a IMP-resistant E.
cloacae in our study.
G. mellonella larvae have recently been used as an
alternative to vertebrates as an invertebrate model host for
studying a number of important human pathogens,Please cite this article in press as: Yang H, et al., Enhanced efficacy
resistant Enterobacter cloacae: in vitro activity and a Galleria mello
(2016), http://dx.doi.org/10.1016/j.jmii.2016.01.003including Gram-positive and -negative bacteria and several
pathogenic fungi.7e10 These insects have sophisticated
cellular and humeral defenses, which are similar to the
innate immune response of mammals, making them highly
attractive for the study of acute bacterial infections.24 We
employed this model to study the in vivo activity of IMP-
COL combination against E. cloacae for the first time in
order to predict their suitability for clinical use in humans.
The combination of IMP and COL was significantly more
effective than either drug alone versus IMP-resistant E.
cloacae when assessed in vivo using the G. mellonella
larvae model of infection. This was in agreement with our
in vitro study and provided preliminary in vivo evidence
that such a combination might be useful therapeutically.
Although our data suggested and somewhat confirmed
that IMP-COL combination demonstrated synergy effects
against IMP-susceptible or -resistant E. cloacae infections,
these results should be considered with care for at least
two reasons. First, the in vitro and in vivo synergy of
antibiotic combinations is often strain- and clone-specific,
and we just investigated two clinical isolates. Finally,
although preliminary evidence of in vivo efficacy can be
obtained through the use of invertebrate-infection models,
additional studies are required using mammalian-infection
models, since it is considered that the data generated are
most relevant to human infections.
In summary, our in vitro and in vivo findings reported
here suggested that IMP-COL combination may be an
effective therapeutic option for the treatment of E.
cloacae infections, although additional studies are
required.Conflicts of interest
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